On 14 October 2016, orphan designation (EU/3/16/1750) was granted by the European Commission to Eiger Biopharmaceuticals Europe Ltd, United Kingdom, for exendin (9-39) for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.
|Disease / condition||
Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.